Reproxalap: Our Novel Small Molecule Drug Candidate for Dry Eye
By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. We believe that reproxalap may have a commercially differentiated product profile versus currently approved drugs for each indication, having shown the potential for early and broad activity in dry eye disease. Additionally, reproxalap, if approved, has added the potential of being the only product that may be able to effectively treat dry eye disease, uniquely addressing the needs of the large underserved population that suffers from this disease. Topical ocular reproxalap has been studied in over 1,100 patients thus far with no observed safety concerns reported. Mild instillation site irritation is the most commonly reported adverse event in clinical trials.
Aldeyra intends to advance 0.25% topical ocular reproxalap, our lead RASP inhibitor, for the treatment of dry eye disease.